Twenty-six patients with metastatic breast cancer were treated with high dose medroxyprogesterone acetate (MAP) p.o. according to currently available pharmacokinetic data (2000 mg/day b.i.d. for 30 days, 1000 mg/day for the following 60 days). Objective response (WHO criteria) was obtained in seven patients (CR + PR = 27%), with good results on visceral and soft tissue localizations; performance status improvement and/or pain relief was obtained in twenty-three (88%). Oral high dose MPA seems to be an effective and well tolerated palliative treatment in advanced breast cancer.
Scheda prodotto non validato
Scheda prodotto in fase di analisi da parte dello staff di validazione
|Titolo:||Oral route administration of medroxyprogesterone acetate (MAP) at high doses in the treatment of advanced breast cancer: Clinical results|
|Citazione:||Guarnieri, A., Tucci, E., & D'Aniello, C. (1984). Oral route administration of medroxyprogesterone acetate (MAP) at high doses in the treatment of advanced breast cancer: Clinical results. CHEMIOTERAPIA, 320-323.|
|Appare nelle tipologie:||1.1 Articolo in rivista|
File in questo prodotto: